Vaccination was one of the ways to control the outbreak of Mpox in the summer of 2022 by limiting transmission of the virus. People are no longer invited to vaccinate and combat this outbreak. However, second vaccinations are still being administered.

Up to and including 6 January 2023, 17,981 first and 11,784 second Mpox vaccinations were administered in the Netherlands.

Even if a person has been vaccinated, it is still important to be alert for symptoms that could indicate Mpox. If you develop symptoms, contact the Municipal Public Health Services (GGDs) immediately to get tested for Mpox, and avoid all direct contact with the skin until the test result is known. It is also important to remember that maximum effectiveness is not achieved until 2 weeks after a second Mpox vaccination.

Side-effects

The Mpox vaccination may cause side-effects. The most common side-effects are: a localised reaction (pain, redness, swelling) at the injection site, as well as non-specific symptoms such as muscle pain, headache, nausea and fever or elevated temperature. Possible side-effects should always be reported to Pharmacovigilance Centre Lareb.

Privacy

RIVM processes personal data to ensure proper management of the Mpox vaccination programme. This privacy statement explains which data will be processed by RIVM and why, and what rights you have when RIVM processes your data.